Autoimmune hemolytic anemia during interferon-beta-I b treatment for multiple sclerosis
- 16 February 2007
- journal article
- other
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 13 (5), 683-685
- https://doi.org/10.1177/1352458506071333
Abstract
A 31-year-old patient with multiple sclerosis (MS), treated with interferon beta-1b (IFNB-1b) for two years, presented with fatigue and dizziness. Coombs' positive autoimmune hemolytic anemia (AIHA) was found. Other potential etiologies of AIHA were ruled out. An association with IFNB-1b was highly suspected. Interferon therapy was discontinued and prednisone therapy instituted. There was resolution of the hemolytic anemia, and prednisone therapy was tapered gradually. To the best of our knowledge, there is no reported case of the development of AIHA associated with IFNB-1b use in MS patients. We conclude that if an unexplained drop in hematocrit occurs with a MS patient receiving IFNB-1b, autoimmune mediated hemolysis should also be considered. Multiple Sclerosis 2007; 13: 683-685. http://msj.sagepub.comKeywords
This publication has 8 references indexed in Scilit:
- Haematological Effects of Interferon-??-1a (Rebif??) Therapy in Multiple SclerosisDrug Safety, 2004
- Immune-Mediated Complications during Interferon Therapy in Hematological PatientsActa Haematologica, 2002
- Autoantibodies in Multiple Sclerosis Patients Before and During IFN-β1b Treatment: Are They Correlated with the Occurrence of Autoimmune Diseases?Journal of Interferon & Cytokine Research, 2002
- Multiple SclerosisNew England Journal of Medicine, 2000
- Autoimmune events during interferon beta-1b treatment for multiple sclerosisJournal of the Neurological Sciences, 1999
- Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapyCancer, 1990
- Alpha-Interferon and Immune Hemolytic AnemiaAnnals of Internal Medicine, 1986
- Clinical toxicity of interferons in cancer patients: a review.Journal of Clinical Oncology, 1986